Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning...
Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to begin enrollment First oral TNF-α inhibitor, if...
Prevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.15 | 13.0434782609 | 1.15 | 1.58 | 1.0669 | 277005 | 1.39438643 | CS |
4 | -0.09 | -6.47482014388 | 1.39 | 1.64 | 1.05 | 255817 | 1.40299807 | CS |
12 | -0.21 | -13.9072847682 | 1.51 | 1.95 | 1.05 | 105998 | 1.43481741 | CS |
26 | -0.7 | -35 | 2 | 2.16 | 1.05 | 80547 | 1.53710958 | CS |
52 | -0.7 | -35 | 2 | 2.16 | 1.05 | 80547 | 1.53710958 | CS |
156 | -0.7 | -35 | 2 | 2.16 | 1.05 | 80547 | 1.53710958 | CS |
260 | -0.7 | -35 | 2 | 2.16 | 1.05 | 80547 | 1.53710958 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관